Roche Diagnostics Corp.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Roche Diagnostics Corp.
Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.
The struggling diagnostics company, initially valued at $5bn, has agreed to be purchased by Roche for a comparatively paltry $295m.
News We’re Watching: May Health PCOS Treatment Shows Promise, Roche Adds Alzheimer’s Assays, Luciole Buys Spiegelberg
This week, May Health’s Ovarian Rebalancing showed promise as a treatment for polycystic ovarian syndrome; a trial of CathWorks’ FFRangio System launched; Roche introduced new assays for Alzheimer’s Disease; Early Health settled data breach allegations; and Boston Scientific added two new board members.
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.